THE SCIENCE
BEHIND Feiolix®
A clinically-validated whole fruit freeze-dried
Feijoa powder for metabolic balance.
Feiolix® is a proprietary freeze-dried powder derived from the fruit of Acca sellowiana, developed to restore insulin sensitivity and improve cardiometabolic health through multi-pathway biological activity.
WHAT’S SO SPECIAL
ABOUT Feiolix®?
Feiolix® is a natural GLP-1 agonist with three key pathways to support GLP-1 secretion.
Backed by emerging human clinical research, Feiolix® delivers measurable outcomes across:
- Glycaemic control
- Endogenous GLP-1 signalling
- Lipid regulation
- Weight management
- Thermogenesis
- Inflammatory regulation
- Appetite modulation
Feiolix® is positioned as a next-generation metabolic ingredient platform, not a single-mechanism botanical.
Clinical Evidence
3
total StudiEs
1
in progress
1
recently
completed
1
peer reviewed
& published
StUDY 1NE.
Feijoa extract clinical study improves hyperglycaemia in patients with T2DM
Population: 24 diabetic individuals over a 3 month period
Dose: 2300mg
Results vs placebo:
- 0.86% reduction in HbA1c (3 month blood glucose average)
- 36.3 mg/dL reduction in fasting blood glucose
- 38 mg/dL reduction in blood triglycerides
- 17.5 mg/dL reduction in total cholesterol
- 18.1 mg/dL reduction in LDL (bad) cholesterol
- 6.7 mmHg reduction in systolic blood pressure
StUDY 2wo.
Ferdinand Study
Population: 97 participants who were prediabetic over a 6 month study period
Dose: 1150mg
Results vs placebo:
- Feiolix significantly reduced fasting plasma glucose compared to placebo over 6 months.
- Feiolix led to sustained reductions in systolic and diastolic blood pressure.
- Feiolix helped maintain weight loss and with lower rebound effect after dietary intervention.
- Feiolix showed lower tendency to rebound for lipid levels and visceral adipose tissue mass.
StUDY 3hree.
A Single Center, Randomised, Double Blind, Placebo-Controlled, Interventional, Comparative Clinical Study to evaluate the Efficacy and Safety of Feiolix Capsules in Prediabetic Participants
Population: 37 participants, pre-diabetic and overweight
Dose: 300mg and 1150mg
Results vs placebo:
- Significantly reduced HBA1c levels (both 1150mg and 300mg)
- Significantly improved response for fasting blood sugar and insulin resistance (300mg)
- Significantly decreased total cholesterol and LDL (both 1150mg and 300mg)
- Significantly reduced body weight and BMI (1150mg) within 2 months
- Significantly reduced eating capacity (1150mg) at 1 and 2 hours, and 1 hour for 300mg (improving satiety).
The Health Benefits of Feijoa –
Mechanistically Defined.
The fruit of Acca sellowiana contains a rare combination of bioactives that act synergistically on metabolic pathways.
Feiolix® concentrates three major bioactive classes:
Abscisic Acid.
Insulin Sensitivity & GLP-1 Modulation
Abscisic acid (ABA) is a conserved signalling molecule found in both plants and humans.
In human physiology, ABA:
- Binds to LANCL2 receptors
- Enhances glucose-dependent insulin secretion
- Stimulates peripheral glucose uptake
- Promotes endogenous GLP-1 release
- Increases mitochondrial gene expression
- Activates brown adipose tissue
- Enhances thermogenesis
- ABA works in a glucose-dependent manner, supporting metabolic regulation without overstimulation.
Ellagitannins > Urolithins.
Inflammation Control & Mitochondrial Function
Feijoa is naturally rich in pedunculagin, an ellagitannin converted by gut microbiota into bioactive urolithins.
Urolithins:
- Reduce pro-inflammatory cytokines
- Improve insulin signalling pathways
- Promote GLP-1 secretion through bitter taste receptors
- Enhance mitochondrial efficiency
- Promote browning of white adipose tissue
- Support adipose tissue remodelling
Chronic low-grade inflammation is a key driver of insulin resistance. Feiolix® targets this upstream mechanism.
Xyloglucan Fibre Matrix.
Glycaemic Modulation & Gut-Metabolic Axis
Abscisic acid (ABA) is a conserved signalling molecule found in both plants and humans.
Xyloglucans are specialised hemicellulose fibres that:
- Slow glucose absorption
- Reduce post-prandial spikes
- Support bile acid metabolism
- Improve triglyceride clearance
- Increase production of propionate via fermentation
Propionate is associated with:
- Improved satiety signalling
- Reduced caloric intake
- Enhanced GLP-1 stimulation
- This gut-metabolic interaction differentiates Feiolix® from isolated ABA ingredients.
THE Feiolix® FACTS.
GLP-1 & Blood
sugar spikes.
When you eat, carbohydrates are broken down into glucose, which enters your bloodstream and causes your blood sugar to rise.
In response, your gut releases hormones like GLP-1 that tell the pancreas to release insulin, reduce glucagon, slow stomach emptying and signal to your brain that you’re getting full.
In a healthy response, blood sugar rises moderately after a meal, GLP-1 and insulin help move glucose into muscles and other tissues, and your levels drift back toward baseline over 2–3 hours without a hard “crash.”
When this system is overloaded by frequent, large spikes—think high-sugar or refined-carb meals—your pancreas has to work harder, insulin levels surge, and over time cells can become less responsive to insulin, a process known as insulin resistance.
These sharp spikes and rapid drops also drive hunger, cravings, low energy, and long-term cardiometabolic risk, which is why moderating post-meal blood sugar and supporting robust GLP-1 signalling are central to modern metabolic health strategies.
Feiolix® is a natural GLP-1 agonist that amplifies your body’s own GLP-1 signalling rather than acting as a single synthetic receptor agonist.
Through its ABA, ellagitannin–urolithin and xyloglucan fibre matrix, Feiolix® promotes endogenous GLP-1 release from gut and pancreatic cells, supports GLP-1 receptor activation, and enhances downstream effects on insulin secretion, satiety signalling and thermogenesis.
This multi-pathway GLP-1 support translates into more stable post-prandial glycaemic responses, reduced appetite, and improved metabolic efficiency without overstimulating glucose-independent pathways.
Feiolix® &
BLOOD SUGAR SPIKES.
Post-meal blood sugar spikes and rapid crashes are central drivers of insulin resistance, hunger, and long-term cardiometabolic risk.
By slowing glucose absorption via its xyloglucan-rich fibre matrix, stimulating GLP-1 and PYY release through gut–microbiome interactions, and improving peripheral glucose uptake via ABA and urolithins, Feiolix® smooths the post-prandial glucose curve rather than simply lowering fasting glucose.
In controlled CGM consumer studies, Feiolix® reduced 30 minute glucose peaks by up to ~35% at breakfast and up to ~50% with high-GI snacks, while extending sustained glucose stability for 21–47%, supporting steadier energy, reduced cravings and a lower glycaemic burden over time.
Multi-Pathway
Mechanism of Action.
Feiolix® operates across five coordinated pathways:
1. Glucose-dependent insulin sensitisation
2. Endogenous GLP-1 modulation
3. Thermogenic activation
4. Inflammatory reduction
5. Gut-metabolic axis regulation
This systems-level activity supports sustainable metabolic restoration throughout the body rather than a single-target intervention.
Clinically, this is reflected in improvements in HbA1c, fasting glucose, lipids, blood pressure, visceral fat and satiety, aligning Feiolix® with current priorities in metabolic health and positioning it as a next-generation GLP-1 supportive ingredient for long-term metabolic balance.
Cardiometabolic
Health Impact.
Across studies, Feiolix® demonstrates improvements in:
- HbA1c
- Fasting glucose
- Insulin sensitivity
- Triglycerides
- LDL cholesterol
- Blood pressure
- Visceral fat markers
- Inflammatory biomarkers
These outcomes align with current clinical priorities in metabolic health management.
**Clinically proven to reduce systolic blood pressure by 10mmhG
Target Bio-Lock™
Technology.
Feiolix® is produced using proprietary Target Bio-Lock™ processing technology.
This ensures:
- Stability of abscisic acid
- Preservation of polyphenols
- Maintenance of fibre architecture
- Standardised bioactive consistency
Target Bio-Lock™ protects the natural fruit matrix synergy critical to efficacy.
Strategic Positioning
Opportunities.
Feiolix® supports innovation in:
- Blood glucose management
- GLP-1 supportive nutrition
- Metabolic syndrome formulations
- Weight management systems
- Women’s metabolic health
- Cardiometabolic health blends
For formulation concepts, claim frameworks and technical documentation, visit our NPD Support section.
A Clinically
Advancing Metabolic
Platform.
Feiolix® combines:
- A whole-fruit bioactive matrix
- Mechanistic validation
- Human clinical data
- Multi-pathway metabolic activity
Positioned at the intersection of nutrition science and metabolic restoration, Feiolix® enables next-generation metabolic health solutions.
